Postes actifs de Nenad Grmusa
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
DEM BioPharma, Inc.
 DEM BioPharma, Inc. Pharmaceuticals: MajorHealth Technology DEM BioPharma, Inc. is an American company that pioneers the next generation of immunotherapeutics to eliminate tumors by targeting 'don't eat me' and 'eat me' signals on cancer cells, macrophages, and other myeloid effector cells. The company is based in Cambridge, MA. The proprietary CHOMP™ platform utilizes CRISPR-based functional genomic screens to discover and validate new signals that could enhance cancer cell elimination through increased phagocytosis. The company was founded by Longwood Fund and builds on groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders. Nenad Grmusa has been the CEO of the company since 2022. | Directeur/Membre du Conseil | 22/09/2022 | - |
| Directeur Général | 22/09/2022 | - |
Historique de carrière de Nenad Grmusa
Anciens postes connus de Nenad Grmusa
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| CHORDIA THERAPEUTICS INC. | Directeur/Membre du Conseil | - | - |
Statistiques
Internationale
| Japon | 2 |
| Etats-Unis | 2 |
Opérationnelle
| Director/Board Member | 2 |
| Chief Executive Officer | 1 |
Sectorielle
| Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CHORDIA THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
DEM BioPharma, Inc.
DEM BioPharma, Inc. Pharmaceuticals: MajorHealth Technology DEM BioPharma, Inc. is an American company that pioneers the next generation of immunotherapeutics to eliminate tumors by targeting 'don't eat me' and 'eat me' signals on cancer cells, macrophages, and other myeloid effector cells. The company is based in Cambridge, MA. The proprietary CHOMP™ platform utilizes CRISPR-based functional genomic screens to discover and validate new signals that could enhance cancer cell elimination through increased phagocytosis. The company was founded by Longwood Fund and builds on groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders. Nenad Grmusa has been the CEO of the company since 2022. | Health Technology |
- Bourse
- Insiders
- Nenad Grmusa
- Expérience
